Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-1875
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Oncology Reports
MedicineCancer ResearchOncology
2018English

P1.03-02 Analysis of SMAD4 Aberrations in Chinese Patients With Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancers
Cancer ResearchOncology
2019English

Targeting SLC1a5-mediated Glutamine Dependence in Non-Small Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2015English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib in the Treatment of Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Lung Cancer: Targets and Therapy
Oncology
2017English

Targeting Angiogenesis in Advanced Non-Small-Cell Lung Cancer: Are Biomarkers Needed?

Current Respiratory Care Reports
2013English

Osimertinib 160 Mg Daily for Advanced Non‐small Cell Lung Cancer With Leptomeningeal Metastasis: A Case Report

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy